Acute myeloid leukemia targets for bispecific antibodies Journal Article

Authors: Hoseini, S. S.; Cheung, N. K.
Article Title: Acute myeloid leukemia targets for bispecific antibodies
Abstract: Despite substantial gains in our understanding of the genomics of acute myelogenous leukemia (AML), patient survival remains unsatisfactory especially among the older age group. T cell-based therapy of lymphoblastic leukemia is rapidly advancing; however, its application in AML is still lagging behind. Bispecific antibodies can redirect polyclonal effector cells to engage chosen targets on leukemia blasts. When the effector cells are natural-killer cells, both antibody-dependent and antibody-independent mechanisms could be exploited. When the effectors are T cells, direct tumor cytotoxicity can be engaged followed by a potential vaccination effect. In this review, we summarize the AML-associated tumor targets and the bispecific antibodies that have been studied. The potentials and limitations of each of these systems will be discussed. © The Author(s) 2017.
Journal Title: Blood Cancer Journal
Volume: 7
Issue: 2
ISSN: 2044-5385
Publisher: Nature Publishing Group  
Date Published: 2017-02-24
Start Page: e522
Language: English
DOI: 10.1038/bcj.2017.2
PROVIDER: scopus
PUBMED: 28157217
PMCID: PMC5386336
Notes: Review -- Export Date: 2 March 2017 -- Source: Scopus
Citation Impact
MSK Authors
  1. Nai-Kong Cheung
    531 Cheung